GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-02-08|

SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center

by GeneOnline
Share To
  • The additional investment for the ‘R&PD Center’ was confirmed by the board of directors committee with a total of 261 million USD
  • SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics

SEONGNAM, South Korea, Feb. 8, 2023 /PRNewswire/ — SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, announced that the company’s board of directors has officially decided to initiate the establishment of the ‘Songdo Global Research & Process Development Center (The R&PD Center).’

Exterior Perspective View of the SK bioscience’s Songdo Global Research & Process Development Center
Exterior Perspective View of the SK bioscience’s Songdo Global Research & Process Development Center

The establishment of the R&PD Center will be proceeded on a 30,413.8㎡ site in Songdo, Republic of Korea with a total investment of 261 million USD(325.7 billion KRW), including the previous investment of 33 million USD(41.9 billion KRW). 

Once the establishment of the R&PD Center is completed in the first half of 2025, the headquarters and the research and development (R&D) center currently located in Pangyo will move to Songdo area.

SK bioscience aims to secure the newest technologies covering the entire process from basic research to commercial manufacturing and to ultimately create a global vaccine ecosystem to preemptively respond to new infectious diseases through the establishment.

To achieve the goal, SK bioscience plans to operate the ‘Open Lab’ in the R&PD Center to strengthen a global vaccine network. The Open Lab will be utilized as a joint research space for international organizations and biopharmaceutical companies around the world to develop new vaccines together with SK bioscience.

Furthermore, collaborations such as manpower training for other countries which do not have enough research capacities but high demand for vaccine development, are planned in the Open Lab. The operation of the Open Lab will help promoting the ‘Glocalization’ business, a project which transfers SK bioscience’s R&D and production capabilities to countries with high demand for vaccines but insufficient human and physical infrastructure, and one of the main future strategies of SK bioscience.

SK bioscience will also secure the advanced BSL-3 (Biological Safety Level) research facilities to further strengthen its own vaccine pipeline.

BSL is a rating standard for biological facilities capable of conducting microbial research under high biohazard levels. BSL-3 level research facilities are required for development of vaccines against new infectious diseases.

In addition, SK bioscience plans to operate a pilot plant to strengthen global competitiveness in the C(D)MO market. A pilot plant, a small-scale test facility utilized before commercializing a new method or a product, will be established at the R&PD. The plant will be designed as a cGMP-level production facility, the highest demanding standard worldwide.

The plant will also be utilized for new tasks under the main growth strategies of SK bioscience such as CGT (Cell and Gene Therapy) mRNA, and viral vectors platforms research. As SK bioscience is planning a future strategy to advance to new markets through JV (Joint Venture) and M&A, the pilot plant is expected to play a key role in leading cooperation and investment with other biopharmaceutical companies.

Since the plant can produce samples for non-clinical, clinical, and commercial-scale, SK bioscience will accelerate expanding its new pipeline through synergy with ‘L-HOUSE’, a vaccine manufacturing facility located in Andong area.

Jaeyong Ahn, CEO of SK bioscience said, "The establishment of the R&PD Center will be a crucial milestone for us to advance the entire vaccine and biopharmaceutical industry beyond Korea to the world. We will ultimately organize the ‘Dream Team’ of the global health network to protect a safe tomorrow for people around the world."

About SK bioscience

SK bioscience is a global innovative vaccine and biotech company, standing committed to global pandemic preparedness in vaccine development and manufacturing to create more equitable access to vaccines. In leveraging strengths on cutting-edge vaccine development technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. Under collaborations of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, SK bioscience has firmly established globally certified R&D and manufacturing technologies. All of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. For further information, please visit

Official SK bioscience Homepage
SK bioscience Linkedin

Contact
SK bioscience Communications Team
Changhyun Jin([email protected])  
Jeannie S. Pak([email protected])  
Tae-Gyun Kim([email protected])

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top